Research programme: chemokine receptor antagonists - ChemoCentryx

Drug Profile

Research programme: chemokine receptor antagonists - ChemoCentryx

Alternative Names: CCX 6239; CCX 9664; CCX 991; CCX-662; CCX587; CCX650

Latest Information Update: 27 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR2 receptor antagonists; CCR9 receptor antagonists; Chemokine receptor antagonists; CXCR4 receptor antagonists; CXCR7 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Metabolic disorders

Highest Development Phases

  • Preclinical Atopic dermatitis; Glioblastoma; Inflammatory bowel diseases; Psoriasis
  • No development reported Metabolic disorders

Most Recent Events

  • 12 May 2016 Preclinical development is still ongoing for Psoriasis in USA
  • 22 May 2014 Research programme: chemokine receptor antagonists - ChemoCentryx is available for licensing as of 22 May 2014.
  • 22 May 2014 No development reported - Preclinical for Metabolic disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top